Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab

Salazar-Mejía, Carlos Eduardo; Oyervides-Juárez, Víctor Manuel; Wimer-Castillo, Blanca Otilia; Vidal-Gutiérrez, Oscar; Garza‐Guajardo, Raquel; Grande, Enrique

doi:10.1016/j.cpccr.2020.100039

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collision tumors in the kidney are rare. To date, there have been 9 reports, including our report, presenting 10 cases of collision tumors composed of ccRCC and CDC (Table 2) [2][3][4][5][6][7][8][9]. Of these 10 patients, 9 were male.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Renal Collision Tumor Composed of Clear Cell Carcinoma and Collecting Duct Carcinoma Treated with Nivolumab and Ipilimumab: Case Report and Literature Review

Szeto

Krenawi

Ben-Arie

et al. 2021

International Journal of Surgery Oncology

View full text Add to dashboard Cite

Introduction and importance: Collision tumors refer to the phenomenon where two or more different and unrelated tumors occur in the same location of an organ and form a single lesion. We present the first case of renal collision tumors composed of clear cell carcinoma (ccRCC) and collecting duct carcinoma (CDC) treated with combined therapy of nivolumab and ipilimumab.Case presentation: An 89-year-old male presented to the emergency room with back pain. Imaging studies demonstrated a large tumor in the left kidney with renal vein thrombosis. After radical nephrectomy, the histopathological report showed collision tumors with ccRCC and CDC components. The patient was included in a treatment protocol based on nivolumab (220 mg) and ipilimumab (73 mg) every 21 days, however, obtaining no clinical responses after 5 cycles of treatments.Clinical Discussion: Immune checkpoint inhibitors have become a new standard of care for patients with advanced ccRCC. However, current literatures showed inconclusive evidence on the efficacy of immune checkpoint inhibitor for metastatic CDC. As collision tumors with ccRCC and CDC components were infrequently reported in the literature, we also discuss the histological and immunohistochemical findings, clinical outcomes, and a literature review on this type of renal collision tumors. Conclusion:CDC is a rare and highly aggressive type of renal neoplasms, with limited treatment choices. More studies are needed to evaluate the efficacy of immune checkpoint inhibitors on CDC and its associated collision tumors.

show abstract

Section: Discussionmentioning

confidence: 95%

“…Adjuvant chemotherapy was used on 2 patients [4,6]. One patient had combined therapy of cabozantinib and nivolumab [3]. One patient was treated with radiotherapy and adjuvant sunitinib [8].…”

Section: Discussionmentioning

confidence: 99%

Renal Collision Tumor Composed of Clear Cell Carcinoma and Collecting Duct Carcinoma Treated with Nivolumab and Ipilimumab: Case Report and Literature Review

Szeto

Krenawi

Ben-Arie

et al. 2021

International Journal of Surgery Oncology

View full text Add to dashboard Cite

show abstract

Case report: A collision tumor of clear cell renal cell carcinoma and clear cell papillary renal cell tumor

Lin,

Guo,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

We report the case of a 51-year-old woman who was initially hospitalized in the respiratory department with cough and fever. Urinary computed tomography (CT) showed two different incidental masses in the right kidney. The patient underwent a radical right nephrectomy without lymph node dissection and postoperative adjuvant treatment. The pathological examination of the surgical specimens showed a collision tumor composed of a clear cell renal cell carcinoma (CCRCC) and a clear cell papillary renal cell tumor (CCPRCT). To the best of our knowledge, this is the first such case reported to date. No recurrence of local or distant metastasis was found during routine follow-up 14 months after the operation.

show abstract

Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab

Cited by 2 publications

References 8 publications

Renal Collision Tumor Composed of Clear Cell Carcinoma and Collecting Duct Carcinoma Treated with Nivolumab and Ipilimumab: Case Report and Literature Review

Renal Collision Tumor Composed of Clear Cell Carcinoma and Collecting Duct Carcinoma Treated with Nivolumab and Ipilimumab: Case Report and Literature Review

Case report: A collision tumor of clear cell renal cell carcinoma and clear cell papillary renal cell tumor

Contact Info

Product

Resources

About